Piramal Pharma’s Mumbai facility gets 6 observations from US FDA inspection

Share it

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity. Shares of Piramal Pharma Ltd ended at ₹196.70, down by ₹3.15, or 1.58%, on the BSE.

Leave a Comment

Your email address will not be published. Required fields are marked *